Рет қаралды 5,012
“I can provide you with aggregate data about rebates provided from the medical companies to the government but they’re covered under commercially confidential deeds for individual medicines.”
•••••••••••••••••••••••••••••
“A court has dismissed an Australian Competition and Consumer Commission appeal in a case in which it alleged Pfizer had used its market power to limit competition for its cholesterol-lowering drug Lipitor.
The ACCC said on Friday it was considering the judgment and remained committed to pursuing cases involving "misuse of market power".
“The ACCC brought this appeal because it was concerned that Pfizer's use of its market position as supplier of the top-selling branded atorvastatin immediately before generic products were able to enter the market harmed the competitive process and therefore consumers," chairman Rod Sims said in a statement.
The drug Lipitor generated annual sales of more than $700 million for Pfizer in Australia before the company's patent expired here in May 2012, the ACCC said when it launched the case against Pfizer in 2014.
The ACCC alleged that Pfizer had offered big discounts and rebates on Lipitor to pharmacies that bought up large quantities of the drug and agreed to limit re-supply of competing generic atorvastatin products.”
••••••••••••••••••••••••••••
"The most popular type of statin has been atorvastatin, which has the brand name Lipitor. It has topped the list of highest expenditure drugs on the PBS for the last decade, costing Australian taxpayers more than $7 billion in total, which has gone to Pfizer, the company holding its patent.
But the expiry of this patent last year means that Pfizer no longer has an exclusive right to sell atorvastatin; many other firms can now produce equivalent formulations of the drug, which are known as generics.
In most countries, governments have moved to make large savings by using low-cost generics. For a widely used drug such as atorvastatin, generics can cost 95% less than the price of the original drug.
A typical dose of atorvastatin (40 milligrams), which went off patent in many countries last year, now costs just a few dollars a month in England, Sweden and New Zealand. In fact, the generic form of atorvastatin is exclusively provided in New Zealand by Pfizer for around $2 a month.
But wait…
Not in Australia. The pricing agreement with the government specified a reduction of only 16% (to around $50 per month for a 40mg dose) and that this price would fixed for 18 months.
As the price of these drugs internationally is so much lower, generic manufacturers offer large discounts on the wholesale price of the medications to pharmacists. And pharmacists get to pocket the difference.
Each time a script for atorvastatin is dispensed, the government pays $50 to a pharmacist to cover the wholesale cost of the drug. If the pharmacist actually purchases generic atorvastatin for $10, she keeps the extra $40 per script flowing from discounts.
The windfall gains from discounts come on top of the $600,000 (on average) the government pays every pharmacy each year for dispensing medications and other incentives, through its agreement with the Pharmacy Guild."
••••••••••••••••••••••••
While it’s important that people get affordable access to important drugs, when $17 billion of taxpayer funds is spent on the PBS it’s important the price being paid for patented and off label drugs is fully disclosed.
Unfortunately that’s not the case, so the taxpayer gets exploited especially in regard to the cost of off label drugs.
The Health Department should not be covering up how much the taxpayer pays for individual drugs. The secrecy suggests we are being ripped off.
Quotes from:
www.smh.com.au...
theconversatio...
#auspol #australia #pbs #offlabel #pfizer #statins